摘要
目的观察口服降糖药(OAD)血糖控制不佳的T2DM患者,分别采用地特胰岛素联合门冬胰岛素和预混胰岛素类似物强化治疗的有效性、安全性。方法选取OAD血糖控制不佳的T2DM患者92例随机分为地特胰岛素联合门冬胰岛素(A组)和预混胰岛素类似物(B组)强化治疗4周。结果 4周后,两组治疗前后FBG、2 h PG、Hb A1c均较基线显著降低(P<0.05),而组间血糖达标时间、达标时胰岛素用量、低血糖发生率差异无统计学意义(P>0.05)。结论地特胰岛素联合门冬胰岛素与预混胰岛素类似物均可有效控制OAD控制不佳的T2DM患者血糖,且低血糖发生率低,安全性高。
Objective To investigate the effectiveness and safety of insulin detemir combined with insulin aspart regimens versus premixed insulin analogue regimens for treating patients with type 2 diabetes in poorglycemic control starting therapy with oral antidiabetic drugs. Methods Ninety-two cases of type 2 diabetes patients who still had poor glycemic control by treatment of OAD were randomized to insulin detemir combined with insulin aspart group（group A）or premixed insulin analogue group（group B）. Patients were received intensive therapy for 4 weeks. Results After 4 weeks treatment, the levels of fasting blood glucose（FBG）, 2-hour postprandial blood glucose（2hPG）and glycated hemoglobin（HbA1c）decreased signiifcantly from baseline （P〈0.05）in both groups. However, there were no signiifcant differences（P〉0.05）in the recovering time of blood glucose, insulin dose and rate of hypoglycemia between two groups. Conclusion Both the treatment of insulin detemir combined with insulin aspart and premixed insulin analogue are safe and effective in controlling the level of blood glucose, and rates of hypoglycemia are low in patients with T2DM who had poor glycemic control by treatment of OAD.
出处
《中国医药指南》
2015年第2期19-20,共2页
Guide of China Medicine
